Background/aim: Altered fractionation is an area of intense clinical research in radiation oncology. Estimation of the α/β ratio of individual carcinomas after establishment of primary cell cultures from tumor biopsies may prove of importance in the individualization of radiotherapy schemes.
Materials And Methods: Here we proposed a simple method to estimate the α/β ratio in cultured cell lines (two lung carcinomas: A549 and H1299; one lung fibroblast cell line: MRC5), using viability assays.
Results: For the A549 cell line, the α/β ratio ranged from 14-25 Gy, for H1299 from 11-43 Gy and for the MRC5 fibroblast cell line this was far lower, ranging from 0.69 to 6 Gy. The α/β ratio decreased when extracted from comparisons of lower dose per fraction schemes.
Conclusion: The α/β ratio of a cell line can be easily defined after simple viability/dose fractionation experiments.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411742 | PMC |
| http://dx.doi.org/10.21873/invivo.11042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata.
J Eur Acad Dermatol Venereol
October 2024
Clifton Insight, Bristol, UK.
Article Synopsis
- * A systematic review and Bayesian network meta-analysis were conducted, analyzing existing randomized controlled trials (RCTs) to evaluate the efficacy and safety of these two drugs at Week 24.
- * The results indicated no significant difference in hair regrowth effectiveness between ritlecitinib and baricitinib, but highlighted the need for more research due to uncertainty and effect modifications found in the analysis.
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis.
Blood Adv
April 2024
Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
The absence of a standardized definition for graft-versus-host disease (GVHD) flares and data on its clinical course are significant concerns. We retrospectively evaluated 968 patients across 23 Mount Sinai Acute GVHD International Consortium (MAGIC) transplant centers who achieved complete response (CR) or very good partial response (VGPR) within 4 weeks of treatment. The cumulative incidence of flares within 6 months was 22%, and flares were associated with a higher risk of nonrelapse mortality (NRM; adjusted hazard ratio [aHR], 4.
View Article and Find Full Text PDFTiron ameliorates acetic acid-induced colitis in rats: Role of TGF-β/EGFR/PI3K/NF-κB signaling pathway.
Int Immunopharmacol
February 2024
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. Electronic address:
Background: Ulcerative colitis (UC), an ongoing inflammatory disorder of the colon, is marked by persistent mucosal surface irritation extending from the rectum to the near-proximal colon. Tiron is a synthetic analogue of vitamin E which is known to have antioxidant and anti-inflammatory effects in various animal models, so the goal of this study was to find out whether Tiron had any preventive impacts on UC inflicted by acetic acid (A.A) exposure in rats.
View Article and Find Full Text PDFClinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
JAMA Dermatol
September 2023
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
Importance: Baricitinib is an oral selective Janus kinase 1/2 inhibitor that has achieved clinically meaningful outcomes for scalp, eyebrow, and eyelash hair regrowth in patients with severe alopecia areata (AA) at week 36 of treatment. Treatment with baricitinib, 4 mg, has resulted in higher response rates than baricitinib, 2 mg, at weeks 36 and 52.
Objective: To determine the efficacy of uptitration to baricitinib, 4 mg, for 24 weeks in patients who had previously not responded to baricitinib, 2 mg (Severity of Alopecia Tool [SALT] score of >20).
Article Synopsis
- The study presents an experimental demonstration of an optics-based half-adder that processes two channels of 4-phase-shift-keying (4-PSK) data using nonlinear wave mixing technology.
- The system takes two sets of 4-ary phase-encoded inputs and produces corresponding outputs labeled as Sum and Carry through a nonlinear device, showcasing multiple phase levels for both inputs and outputs.
- Experimental findings indicate that the half-adder achieves specific conversion efficiencies for data outputs, with low optical signal-to-noise ratio penalties at varying symbol rates, confirming its effectiveness in high-speed optical communication.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!